Financials

v3.7.0.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 10,870 $ 14,006
Receivables 1,009 3,587
Prepaid expenses and other current assets 433 237
Total current assets 12,312 17,830
Property and equipment, net 762 837
Total assets 13,074 18,667
Current liabilities:    
Accounts payable 1,537 3,015
Accrued clinical trials expenses 189 1,387
Other accrued liabilities 544 455
Total current liabilities 2,270 4,857
Warrant liabilities 197 619
Total Liabilities 2,467 5,476
Commitments and contingencies
Stockholders’ equity:    
Common stock, at amounts paid-in 297,855 297,855
Additional paid-in capital 24,721 24,300
Accumulated deficit (311,969) (308,964)
Total stockholders’ equity 10,607 13,191
Total liabilities and stockholders' equity $ 13,074 $ 18,667

Source

v3.7.0.1
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Revenues:    
License revenue $ 40 $ 0
Total revenue 40 0
Operating expenses:    
Research and development 2,126 700
General and administrative 1,351 1,131
Total operating expenses 3,477 1,831
Loss from operations (3,437) (1,831)
Other income (expense):    
Other income (expense), net 10 (19)
Non-cash gain on changes in the fair value of warrants 422 4
Other income (expense), net 432 (15)
Net loss and comprehensive loss $ (3,005) $ (1,846)
Basic net loss per common share $ (0.14) $ (0.09)
Diluted net loss per common share $ (0.16) $ (0.09)
Weighted average shares used in computing basic net loss per common share 21,199 20,060
Weighted average shares used in computing diluted net loss per common share 21,376 20,400

Source

v3.7.0.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash flows from operating activities:    
Net loss $ (3,005) $ (1,846)
Adjustments to reconcile loss to net cash used in operating activities:    
Depreciation and amortization 101 93
Non-cash gain on changes in fair value of warrants (422) (4)
Stock-based compensation 421 332
Changes in operating assets and liabilities:    
Receivables 2,578 (644)
Prepaid expenses and other assets (196) (196)
Accounts payable and other accrued liabilities (2,587) 227
Net cash used in operating activities (3,110) (2,038)
Cash flows from investing activities:    
Purchases of furniture and equipment (26) (57)
Net cash used in investing activities (26) (57)
Cash flows from financing activities:    
Net decrease in cash and cash equivalents (3,136) (2,095)
Cash and cash equivalents at beginning of period 14,006 7,857
Cash and cash equivalents at end of period $ 10,870 $ 5,762

Source